ORMP Oramed Pharmaceuticals Inc. stock chart & analysis
Conviction 66HealthcareScan · Fri, Nov 6, 2026Oramed Pharmaceuticals Inc. (ORMP) closed at $3.86 (-0.77%) on Nov 6, 2026. Price is below its 50-day and below its 200-day moving average. RSI(14) 33, RS Rating 93, -29.4% from its 52-week high, +35.4% year to date. Sector: Healthcare · Pharmaceutical Preparations.
Financials as of Tue, Jun 30, 2026 · quarterly.
ORMP technical analysis
Trend
ORMP's moving averages are mixed — no clean uptrend or downtrend. It closed 13.5% below the 50-day ($4.46) and 4.5% below the 200-day ($4.04). ADX(14) at 29 points to a strong, established trend. It meets 4 of 8 trend-template criteria.
Momentum
RSI(14) is 33, in the bearish half of its range. MACD crossed below its signal line on the latest session. Its RS Rating of 93 puts its weighted 12-month performance ahead of about 93% of the US market.
Volume and volatility
Volume on the latest session ran 0.4× its 20-day average. It trades about $483,873 a day on average. ATR(14) is $0.1531, 4.0% of price — its typical daily range. Bollinger Bands are in a squeeze (5 sessions) — volatility is compressed. On-balance volume is trending down. Chaikin Money Flow (-0.15) shows distribution.
Key levels
The chart pattern's support is $3.97 and its resistance $4.74. The 52-week range is $2.09 to $5.47; price is 29.4% below the high and 84.7% above the low. The VWAP anchored at the 52-week high is $4.56, above price.
Performance
ORMP returned -6.1% (1 week), -8.1% (1 month), -8.1% (3 months), -5.6% (6 months), +72.3% (1 year), +35.4% (year to date).
About Oramed Pharmaceuticals Inc.
Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.
Pharmaceutical Preparations · Listed 2004 · 13 employees
Congress activity
Disclosed STOCK Act trades in ORMP · 1 recent
| Member | Side | Amount | Traded | Filed | PTR |
|---|---|---|---|---|---|
 Brad Knott house · R · NC · traded 2025-01-10 | Sell | $15K–$50K | 2025-01-10 | 2025-02-25 |
SEC filings
EDGAR filings in ORMP · 10 recent
Get daily signals & real-time alerts.
StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 7 days, no credit card.
Start free — 7-day trial, no card →Free daily signals by email. Top 3 setups per lane after every close. No account needed.
Unsubscribe anytime · Privacy
Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.